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Summary
Background.— Statins have favourable effects on lipid proﬁles, decrease total mortality and
have many pleiotropic effects.
Aims.— To determine and compare the pleiotropic effects of simvastatin and ezetimibe in
dyslipidaemic patients.
Methods.— Forty-four patients (20 postmenopausal women) with low-density lipoproteinLipid cholesterol >130mg/dL (or >100mg/dL in patients with coronary artery disease or its equiv-
alent) were treated with simvastatin 10mg daily (n = 21) or ezetimibe 10mg daily (n = 23). In
blood samples taken before and three months after treatment, we measured the concentration
of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein
cholesterol, apolipoprotein A, apolipoprotein B, lipoprotein(a), homocysteine, tissue factor, von
Willebrand’s factor and C-reactive protein.
Abbreviations: CRP, C-reactive protein; ELIZA, Enzyme-linked immunosorbent assay; HDL, High-density lipoprotein; LDL, Low-density
ipoprotein; TF, Tissue factor; vWf, von Willebrand’s factor.
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Results Baseline lipid proﬁles and haematological variables were similar in both groups. Sim-
vastatin and ezetimibe decreased the concentrations of total cholesterol (262 to 189mg/dL,
p < 0.001, and 268 to 220mg/dL, p = 0.001, respectively), low-density lipoprotein cholesterol
(177 to 114mg/dL, p < 0.001 and 196 to 146mg/dL, p < 0.001, respectively) and C-reactive pro-
tein (1.2 to 0.3mg/dL, p = 0.001 and 2.8 to 0.8mg/dL, p = 0.005, respectively). Simvastatin also
reduced the concentration of apolipoprotein B (125 to 93mg/dL, p < 0.001).
Conclusion.— Both drugs improved lipid proﬁles and C-reactive protein concentration. However,
no inﬂuence was found on tissue factor or von Willebrand’s factor. Our results suggest that C-
reactive protein lowering may occur in conjunction with low-density-lipoprotein cholesterol
lowering and not through a speciﬁc statin pleiotropic anti-inﬂammatory effect.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— Les statines ont un effet favorable sur le proﬁl lipidémique, diminuent la mortalité
totale et présentent aussi plusieurs actions pléiotropiques. Le but de cette étude était de
déterminer et comparer les effets pléiotropiques de simvastatin et d’ezetimibe aux malades
dyslipidémiques.
Méthodes.— Quarante-quatre malades (20 femmes postmenopausales) avec basse densité
lipoprotéine de cholestérol supérieure à 130mg/dL ou basse densité lipoprotéine de cholestérol
supérieure à 100mg/dL (personnes avec maladie d’artère coronaire ou ses équivalents), ont été
traités avec simvastatin (n = 21) ou ezetimibe (n = 23), 10mg par jour. Dans tous les échan-
tillons (avant et trois mois après le traitement), on a mesuré les niveaux de cholestérol
total, triglycérides, grande densité lipoprotéine de cholestérol, basse densité lipoprotéine de
cholestérol, apolipoprotéine A, apolipoprotéine B, lipoprotéine(a), homocystéine, facteur du
tissu, von Willebrand et protéine C-réactive.
Résultats.— Les prix premiers des lipides et des paramètres hématologiques ont été pareils dans
les deux groupes. Simvastatin et ezetimibe ont diminué cholestérol total (262 à 189mg/dL ;
p < 0,001 et 268 à 220mg/dL ; p = 0,001, respectivement), basse densité lipoprotéine de
cholestérol (177 à 114mg/dL ; p < 0,001 et 196 à 146mg/dL ; p < 0,001, respectivement) et pro-
téine C-réactive (1,15 à 0,3mg/dL ; p = 0,001 et 2,8 à 0,8mg/dL ; p = 0,005, respectivement).
En plus, simvastatin a diminué apolipoprotéine B (125 à 93mg/dL ; p < 0,001).
Conclusions.— Les deux médicaments ont amélioré le proﬁl lipidémique des malades et les
niveaux de protéine C-réactive. Pourtant, aucune inﬂuence sur facteur du tissu ni sur von
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[Willebrand n’a été trouvé.
© 2010 Elsevier Masson SAS.
Background
Simvastatin, like all other statins, is an inhibitor of
3-hydroxy-3-methyl-glutaryl-CoA reductase [1]— a key
enzyme in the cholesterol-synthesis pathway. Statins have
proven to be especially effective in reducing the concentra-
tion of low-density lipoprotein (LDL) cholesterol and, to a
lesser extent, that of triglycerides [2]. Furthermore, when
administered in either primary or secondary prevention of
coronary heart disease, statins reduce coronary morbidity
and mortality effectively [3]. Until recently, it was believed
that the beneﬁcial effects of statins were due solely to
their lipid-lowering actions [4—8]. Several studies [9,10]
have reported that besides their beneﬁcial inﬂuence on
lipid proﬁles, statins have additional, or pleiotropic, effects
[11]. These studies examined a variety of disorders, and
showed various beneﬁts, ranging from an improvement in
bone mineral density [12] to a reduction in the incidence
of Alzheimer’s disease [13]. Furthermore, the Scandinavian
Simvastatin Survival Study [14] and the Heart Protection
Study [15] demonstrated that simvastatin therapy improves
endothelial function, which is a strong and an independent
predictor of cardiovascular events [16].
p
u
p
vs droits réservés.
Ezetimibe is an intestinal cholesterol absorption
nhibitor. Actually, in contrast to statins, ezetimibe reduces
eeding cholesterol concentration without any effect on
he absorption of triglycerides, fat acids, cholic acids
nd fat-soluble vitamins [17]. Concerning pleiotropic
ffects, ezetimibe therapy does not improve endothelium-
ependent vasodilation, despite the reduction in LDL
holesterol serum concentration [18].
Tissue factor (TF), formerly known as thromboplastin,
s a cell surface glycoprotein, synthesized and expressed
y a wide variety of cells [19,20]. Accumulating evi-
ence presents TF as a multifaceted transmembrane
ignalling receptor involved in the regulation of angiogen-
sis, tumour growth, metastasis and inﬂammation [21].
levated concentrations of TF are observed in patients
ith hypertension, diabetes mellitus or dyslipidaemia, in
mokers, and in those with acute coronary syndromes
22].
Von Willebrand’s factor (vWf) is a protein that ensures
rothrombotic factor VIII binding and transport, and reg-
lates platelet adhesion (to the appropriate receptors),
latelet accumulation and thrombus formation [23]. Plasma
Wf is increased in patients with major risk factors for
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therosclerosis and in documented cardiovascular disease
24,25].
C-reactive protein (CRP) is a circulating inﬂammatory
arker that promotes thrombosis and may also promote
rterial and tissue damage by several mechanisms [26].
RP may contribute not only to the prognosis of coronary
yndromes and acute stroke, but also to the predic-
ion of cardiovascular events in the general population
27].
The objective of the present study was to assess the
ffect of simvastatin or ezetimibe therapy on the concen-
ration of TF, vWf and CRP, after similar reductions in LDL
holesterol concentration by both drugs.
ethods
ubjects
orty-four patients with mild hypercholesterolaemia (total
holesterol≈ 265mg/dL) were selected to ensure similar
eductions in LDL cholesterol concentration after the admin-
stration of simvastatin or ezetimibe. All patients were
rom the Lipid Clinic of the Onassis Cardiac Surgery Cen-
re, Athens, Greece. The centre’s Institutional Review
oard approved the study. The diagnosis for mild hyperc-
olesterolaemia was based on the following criteria: total
holesterol >240mg/dL and LDL cholesterol >130mg/dL; or
DL cholesterol >100mg/dL in patients with coronary artery
isease or its equivalent; or LDL cholesterol >70mg/dL in
atients with coronary artery disease and diabetes mellitus
r metabolic syndrome or restenosis or multiple risk factors
r who were smokers [28]. Smokers were deﬁned as cur-
ent or ex-smokers; non-smokers were deﬁned as those who
ad never smoked. Women were deﬁned as postmenopausal
hen they reported their last menses to have been at least
2months earlier; they were not on hormone replacement
herapy. Heavy drinking, liver and renal disease, obesity and
iabetes mellitus, hypothyroidism and professional sport
ctivity were exclusion criteria.
The subjects were divided into two groups: 23 patients
11men and 12 postmenopausal women) were treated
ith ezetimibe 10mg daily while 21 patients (13men and
ight postmenopausal women) were treated with simvas-
atin 10mg daily. Blood samples were drawn before and
months after the treatment. In both samples we mea-
ured the concentration of total cholesterol, triglycerides,
igh-density lipoprotein (HDL) cholesterol, LDL cholesterol,
polipoprotein A, apolipoprotein B, lipoprotein(a), homocys-
eine, TF, vWf and CRP. Patients were selected randomly and
ere matched for age, sex, body mass index, lipid proﬁle
nd haematological variables.
etermination of blood lipids
lasma total cholesterol, triglycerides and HDL cholesterol
oncentrations were measured using enzymatic colori-
etric methods on a Roche Integra Biochemical analyser,
ith commercially available kits (Roche Diagnostics Gmbh,
annheim, Germany). Serum LDL cholesterol concentration
as calculated using the Friedewald’s formula [29] in
atients with a triglyceride concentration <400mg/dL.
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polipoprotein A, apolipoprotein B and lipoprotein(a)
oncentrations were measured by nephelometry (Neph-
lometer: BN-100, Behring, Germany). Blood glucose
oncentration was measured by the hexokinase method
ith a Dade Behring reagent on a Dimension instrument
Dade Behring, Liederbach, Germany). Homocysteine
oncentration was calculated using the Axsym Abbott
ethod, vWf plasma concentration was deﬁned by the con-
ealed method and TF concentration by an enzyme-linked
mmunosorbent assay (ELIZA), and CRP concentration was
easured by immunonephelometry.
tatistical analysis
ost-hoc power analysis showed that the differences found
n total cholesterol in both subgroups and the sample size
f the study produced a statistical power of 61.02% at a
igniﬁcance level of p < 0.05. Owing to the non-normal dis-
ribution of continuous variables, non-parametric statistics
ere used. The aforementioned variables are presented
s medians and interquartile ranges, while categorical
ariables are shown as absolute and relative frequen-
ies (percentages). In order to assess any differences at
aseline or after 3months, the Mann-Whitney statistic
as used. Any differences in the distribution of contin-
ous variables between the start and the end of the
tudy were evaluated using the Wilcoxon sign-rank test for
oth treatment groups. The potential association between
ategorical variables and treatment was tested using Pear-
on’s Chi2 statistic. In order to adjust for the inﬂation of
ype I error due to the large number of multiple compar-
sons, we used the Bonferroni correction, setting a new
evel of p-value, which was considered to be signiﬁcant if
0.001 for each two-sided test. Data were analysed using
TATATM (Version 9.0, Stata Corporation, College Station, TX,
SA).
esults
aseline characteristics
he clinical and biochemical characteristics of the two
roups are shown in Table 1. As expected, given the study
esign, there were no signiﬁcant differences between the
wo patient groups in terms of age, body mass index (calcu-
ated as weight divided by height squared and expressed in
g/m2), waist circumference or baseline lipid and haema-
ological variables. There were no signiﬁcant differences
etween the two groups in terms of sex, number of smokers
r frequency of diabetes mellitus or coronary heart dis-
ase.
hanges in lipid, CRP and haematological
oncentrations after simvastatin treatmenthere were signiﬁcant reductions in the concentrations of
otal cholesterol, LDL cholesterol, apolipoprotein B and CRP
Table 2). There were no signiﬁcant differences in the con-
entrations of lipoprotein(a), homocysteine, vWf or TF after
reatment with simvastatin (Table 2).
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Table 1 Clinical and biochemical characteristics of both groups.
Ezetimibe (n = 23) Simvastatin (n = 21) p
Age (years) 57 ± 19 57 ± 17 0.86
Height (cm) 1.7 ± 0.2 1.7 ± 0.1 0.62
Weight (kg) 80 ± 21 82 ± 15.8 0.59
Waist (cm) 99 ± 15 98 ± 11.5 0.49
Body mass index (kg/m2) 26.9 ± 5.7 28.1 ± 4.2 0.57
Total cholesterolb (mg/dL) 268 ± 38 262 ± 57 0.29
Triglyceridesb (mg/dL) 138 ± 84 117 ± 75 0.79
High-density lipoproteinb (mg/dL) 52 ± 11 50 ± 17.6 0.81
Low-density lipoproteinb (mg/dL) 196 ± 43 177 ± 52.3 0.13
Apolipoprotein Ab (mg/dL) 143 ± 41 145 ± 32 1.00
Apolipoprotein Bb (mg/dL) 123 ± 29 125 ± 26.5 0.89
Lipoprotein(a)b (mg/dL) 16 ± 25.6 32 ± 56.5 0.32
Glucoseb (mg/dL) 94 ± 24 98 ± 34.5 0.12
Total cholesterola (mg/dL) 220 ± 38 189 ± 52 0.001
Triglyceridesa (mg/dL) 108 ± 71 112 ± 37.5 1.00
HDL cholesterola (mg/dL) 54 ± 12 52 ± 19 0.66
LDL cholesterola (mg/dL) 146 ± 37 114 ± 36 <0.001
Apolipoprotein Aa (mg/dL) 142 ± 40 159 ± 26 0.43
Apolipoprotein Ba (mg/dL) 108 ± 27 93 ± 28 0.04
Lipoprotein(a)a (mg/dL) 13 ± 34 20 ± 60.4 0.42
Glucosea (mg/dL) 98 ± 15 104 ± 30 0.12
Systolic blood pressure (mmHg) 128 ± 20 120 ± 18.5 0.99
Homocysteineb (mol/L) 11.3 ± 5.7 10.5 ± 4.2 0.17
von Willebrand’s factorb (g/mL) 120 ± 71 113 ± 36.5 0.93
Tissue factorb (g/mL) 25.2 ± 25.2 23.2 ± 26.2 0.96
C-reactive proteinb (mg/L) 2.8 ± 4.6 1.145 ± 3.0 0.26
Homocysteinea (mol/L) 11 ± 4.2 10.6 ± 4.8 0.87
von Willebrand’s factora (g/mL) 126 ± 78 117 ± 43.5 0.97
Tissue factora (g/mL) 32.16 ± 30.5 22 ± 27.8 0.20
C-reactive proteina (mg/L) 0.8 ± 1.4 0.3 ± 2.2 0.23
Diastolic blood pressure (mmHg) 75 ± 10 80 ± 10 0.50
HDL: high-density lipoprotein; LDL: low-density lipoprotein. Data are medians± interquartile ranges.
a Concentration after drug administration.
b Concentration before drug administration.
Table 2 Lipid, C-reactive protein and haematological changes after simvastatin treatment.
Concentration before drug
administration
Concentration after drug
administration
p
Total cholesterol (mg/dL) 262 ± 57 189 ± 52 <0.001
Triglycerides (mg/dL) 117 ± 75 112 ± 37.5 0.07
HDL cholesterol (mg/dL) 50 ± 17.6 52 ± 19.0 0.44
LDL cholesterol (mg/dL) 177 ± 52.3 114 ± 36 <0.001
Apolipoprotein A (mg/dL) 145 ± 32 159 ± 26 0.07
Apolipoprotein B (mg/dL) 125 ± 26.5 93 ± 28 <0.001
Lipoprotein(a) (mg/dL) 32 ± 56.5 20 ± 60.4 0.72
Glucose (mg/dL) 98 ± 34.5 104 ± 30 0.38
Homocysteine (mol/L) 10.5 ± 4.2 10.6 ± 4.8 0.55
von Willebrand’s factor (g/mL) 113 ± 36.5 117 ± 43.5 0.66
Tissue factor (g/mL) 23.2 ± 26.2 22 ± 27.8 0.61
C-reactive protein (mg/L) 1.15 ± 3.0 0.3 ± 2.2 0.004a
HDL: high-density lipoprotein; LDL: low-density lipoprotein. Data are medians± interquartile ranges.
a Not considered to be signiﬁcant if ‘Bonferroni’ correction is used.
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Table 3 Lipid, C-reactive protein and haematological changes after ezetimibe treatment.
Concentration before drug
administration
Concentration after drug
administration
p
Total cholesterol (mg/dL) 268 ± 38 220 ± 38 0.001
Triglycerides (mg/dL) 138 ± 84 108 ± 71 0.10
HDL cholesterol (mg/dL) 52 ± 11 54 ± 12 0.42
LDL cholesterol (mg/dL) 196 ± 43 146 ± 37 <0.001
Apolipoprotein A (mg/dL) 143 ± 41 142 ± 40 0.52
Apolipoprotein B (mg/dL) 123 ± 29 108 ± 27 0.063
Lipoprotein(a) (mg/dL) 16 ± 25.6 13 ± 34 0.99
Glucose (mg/dL) 94 ± 24 98 ± 15 0.14
Homocysteine (mol/L) 11.3 ± 5.7 11 ± 4.2 0.080
von Willebrand’s factor (g/mL) 120 ± 71 126 ± 78 0.25
Tissue factor (g/mL) 25.2 ± 25.2 32.2 ± 30.5 0.12
C-reactive protein (mg/L) 2.8 ± 4.6 0.8 ± 1.4 0.005a
HDL: high-density lipoprotein; LDL: low-density lipoprotein. Data are m
a Not considered to be signiﬁcant if ‘Bonferroni’ correction is used.
Changes in lipid, CRP and haematological
concentrations after ezetimibe treatment
There were signiﬁcant reductions in the concentrations of
total cholesterol, LDL cholesterol and CRP (Table 3). There
were no signiﬁcant differences in the concentrations of
lipoprotein(a), homocysteine, vWf or TF after treatment
with ezetimibe (Table 3).
Drug comparison in terms of lipid, CRP and
haematological changes
Simvastatin treatment provides greater lipid-lowering efﬁ-
cacy compared with ezetimibe treatment, leading to greater
reductions in the concentrations of total cholesterol (28% vs
18% respectively, p = 0.001), LDL cholesterol (36% vs 25.5%,
Figure 1. Comparison of the effects of ezetimibe and simvas-
tatin on lipids and C-reactive protein, in terms of percentage
change in concentration. apoB: apolipoprotein B, p < 0.001; CRP:
C-reactive protein, p = 0.001; LDL: low-density lipoprotein choles-
terol, p < 0.001; TC: total cholesterol, p = 0.001.
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espectively, p < 0.001) and CRP (74% vs 71%, respectively,
= 0.001). After simvastatin administration, but not ezetim-
be administration, there was a signiﬁcant reduction in the
oncentration of apolipoprotein B (26%, p < 0.001; Fig. 1).
iscussion
oth drugs improved lipid proﬁles, lowering total choles-
erol and LDL cholesterol concentrations and improving CRP
oncentration. Furthermore, simvastatin treatment reduced
polipoprotein B concentration. However, neither drug had
n inﬂuence on TF or vWf.
CRP may contribute, not only to the prognosis of coro-
ary syndromes and acute stroke, but also to the prediction
f cardiovascular events in the general population [27].
his study and others before [30] have demonstrated that
oth simvastatin and ezetimibe can reduce CRP concen-
ration. Ridker [31] identiﬁed the effect of statins on CRP
oncentration and suggested that it could be used as an
ndicator to evaluate the effectiveness of statin treatment
n patients with elevated LDL cholesterol concentration,
nd also in those with very high CRP concentration. In
articular, the Justiﬁcation for the Use of Statins in Primary
revention: an Intervention Trial Evaluating Rosuvastatin
JUPITER) study [32] suggests that increased high-sensitivity
RP concentration may be useful in making decisions about
he initiation of statin therapy for the primary prevention
f vascular disease.
The importance of TF is due to its potential role in
he coagulation pathway [33]. TF expression abnormalities
ay lead to the pathogenesis of intravascular thrombo-
is, and increased TF concentration and activity have been
ound in atherectomy specimens from patients with unsta-
le angina or myocardial infarction compared with patients
ith stable angina [34]. In the future, it is possible that an
levated TF concentration may ‘predict’ coronary events
n patients with unstable angina [35]. On the other hand,
Wf is important not only in haemostasis but also in throm-
us formation, especially in small vessels under conditions
f high shear stress [36]. Increased vWf concentrations are
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found in patients with high atheromatosis risk and known
cardiovascular disease, and are associated with poor progno-
sis for these patients [25,37]. Statin administration reduces
TF expression in endothelial and vascular smooth mus-
cle cells [38]. Bea et al. demonstrated that simvastatin
inhibits TF expression in advanced atherosclerotic lesions
in apolipoprotein E-deﬁcient mice, independently of lipid
blood concentrations [39]. Also, there are studies indicat-
ing some pleiotropic effects after ezetimibe administration
[40,41]. The fact that the present study did not demonstrate
any signiﬁcant reduction in TF or vWf concentration may be
due to the small number of patients, although there have
been studies with smaller patient numbers that have shown
statins to have pleiotropic effects [19].
One explanation could be that studies indicating statin
pleiotropic effects involve patients with coronary heart dis-
ease [42]. In our study, only 11% of patients presented with
coronary heart disease. Also, it is possible that the mild
hypercholesterolaemia that these patients presented with
and the mild reduction in LDL cholesterol after drug admin-
istration (LDL cholesterol decrease must be >30% [19]) are
responsible for the lack of effect on TF and vWf concen-
trations after drug treatment. On the other hand, it is not
possible to give ezetimibe in a dose >10mg/dL, which there-
fore restricted the simvastatin dose to 10mg/dL. Moreover,
the Ezetimibe and Simvastatin in Hypercholesterolemia
Enhances Atherosclerosis Regression (ENHANCE) study [43]
demonstrated that the addition of ezetimibe to simvastatin
treatment did not improve the pleiotropic effects of ezetim-
ibe. Also, a greater reduction in the vWf concentration was
probably not possible in the present study, because vWf fast-
ing concentrations were almost normal [44] in both patient
groups.
There are some limitations to this study. One reason for
the small number of patients was that the subjects had to be
matched in both groups, with similar baseline lipid proﬁles
and haematological variables, which led to a small number
of patients being selected. The same problem (relatively
small sample size) was an important factor that contributed
to the low (61.02%) statistical power of the study, leading to
limited conclusions. The methods used for the measurement
of haematological variables (vWf plasma concentration was
deﬁned by the congealed method, TF by ELIZA) probably
inﬂuenced the ﬁnal results. ELIZA has been used for TF mea-
surement in other studies [45,46], while Chan et al. [47] used
sodium dodecyl sulphate polyacrylamide gel electrophoresis
for TF determination and Lee et al. [44] used ELIZA for vWf
determination. Also, the maximum dose of ezetimibe that
can be given is 10mg/dL, which restricted the dose of sim-
vastatin to 10mg/dL to ensure that similar reductions in LDL
cholesterol concentration were achieved; this may explain
the lack of pleiotropic effects (i.e., changes in TF or vWf
concentrations). Although there was not the same reduc-
tion in LDL cholesterol concentration in the two groups, both
drugs reduced CRP concentration signiﬁcantly (ezetimibe by
71% and simvastatin by 74%).Conclusions
The lipid proﬁle of both groups was improved after drug
administration, with better results achieved after simvas-
[31
atin treatment. Both drugs also reduced CRP concentration.
owever, neither simvastatin nor ezetimibe affected the
oncentration of TF or vWf. Our results suggest that CRP
owering may occur in conjunction with LDL cholesterol
owering and not through a speciﬁc statin pleiotropic anti-
nﬂammatory effect.
onﬂict of interest
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